Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary

MT Newswires Live

Dec 09, 2025

Shares of Immutep (ASX:IMM) rose 25% in recent Tuesday trade after the company said in a late Monday filing that its unit entered a partnership with a subsidiary of Indian firm Dr. Reddy's Laboratories.

The partnership covers the commercialization of Eftilagimod Alfa, the company's drug candidate for the treatment of non-small cell lung cancer, in all countries outside North America, Europe, Japan, and Greater China, the filing said.

Under the deal, the company will supply the product to Dr. Reddy's in the licensed markets, the filing added.

The company will also hold the global manufacturing rights to the product and retain all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.

It will receive an upfront payment of $20 million from Dr. Reddy's, along with potential regulatory development and commercial milestone payments of up to $349.5 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590641613"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590641613\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590641613?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 07:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590641613","market":"us","top_or_hot":-1,"title":"Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary","media":"MT Newswires Live","content":"<html><body><p> Shares of Immutep (ASX:IMM) rose 25% in recent Tuesday trade after the company said in a late Monday filing that its unit entered a partnership with a subsidiary of Indian firm Dr. Reddy's Laboratories.</p><p>The partnership covers the commercialization of Eftilagimod Alfa, the company's drug candidate for the treatment of non-small cell lung cancer, in all countries outside North America, Europe, Japan, and Greater China, the filing said.</p><p>Under the deal, the company will supply the product to Dr. Reddy's in the licensed markets, the filing added.</p><p>The company will also hold the global manufacturing rights to the product and retain all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.</p><p>It will receive an upfront payment of $20 million from Dr. Reddy's, along with potential regulatory development and commercial milestone payments of up to $349.5 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 07:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shares of Immutep (ASX:IMM) rose 25% in recent Tuesday trade after the company said in a late Monday filing that its unit entered a partnership with a subsidiary of Indian firm Dr. Reddy's Laboratories.</p><p>The partnership covers the commercialization of Eftilagimod Alfa, the company's drug candidate for the treatment of non-small cell lung cancer, in all countries outside North America, Europe, Japan, and Greater China, the filing said.</p><p>Under the deal, the company will supply the product to Dr. Reddy's in the licensed markets, the filing added.</p><p>The company will also hold the global manufacturing rights to the product and retain all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.</p><p>It will receive an upfront payment of $20 million from Dr. Reddy's, along with potential regulatory development and commercial milestone payments of up to $349.5 million.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590641613","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590641613","pubTimestamp":1765237273,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shares of Immutep  rose 25% in recent Tuesday trade after the company said in a late Monday filing that its unit entered a partnership with a subsidiary of Indian firm Dr. Reddy's Laboratories.The partnership covers the commercialization of Eftilagimod Alfa, the company's drug candidate for the treatment of non-small cell lung cancer, in all countries outside North America, Europe, Japan, and Greater China, the filing said.Under the deal, the company will supply the product to Dr. Reddy's in the licensed markets, the filing added.The company will also hold the global manufacturing rights to the product and retain all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.It will receive an upfront payment of $20 million from Dr. Reddy's, along with potential regulatory development and commercial milestone payments of up to $349.5 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","IMM.AU":"IMMUTEP LTD"},"translate_title":"Immutep与印度制药商子公司达成交易后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1},"content_text":"Shares of Immutep (ASX:IMM) rose 25% in recent Tuesday trade after the company said in a late Monday filing that its unit entered a partnership with a subsidiary of Indian firm Dr. Reddy's Laboratories.The partnership covers the commercialization of Eftilagimod Alfa, the company's drug candidate for the treatment of non-small cell lung cancer, in all countries outside North America, Europe, Japan, and Greater China, the filing said.Under the deal, the company will supply the product to Dr. Reddy's in the licensed markets, the filing added.The company will also hold the global manufacturing rights to the product and retain all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.It will receive an upfront payment of $20 million from Dr. Reddy's, along with potential regulatory development and commercial milestone payments of up to $349.5 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}